You are here

  • Home
  • Archive
  • Volume 11, Issue Suppl 2
  • 1532 A phase 1/2 study of safety, tolerability, and pharmacokinetics of SNS-101, a pH-sensitive anti-VISTA mAb, as monotherapy and in combination with cemiplimab in patients with advanced solid tumors

Article metrics

Article menu

Download PDFPDF

Late-Breaking Abstracts
Clinical Trial in Progress
1532 A phase 1/2 study of safety, tolerability, and pharmacokinetics of SNS-101, a pH-sensitive anti-VISTA mAb, as monotherapy and in combination with cemiplimab in patients with advanced solid tumors

 

Online download statistics by month:

Online download statistics by month: October 2023 to June 2025

AbstractFullPdf
Oct 2023801
Nov 2023194021
Dec 20235507
Jan 20243001
Feb 202452011
Mar 202424012
Apr 20244803
May 20243403
Jun 20242404
Jul 20242805
Aug 20243208
Sep 20242803
Oct 20242705
Nov 202463010
Dec 202458013
Jan 202554059
Feb 20252206
Mar 20250010
Apr 2025004
May 2025003
Jun 20250010
Total7810199